From: Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Drug | Brand name | Manufacturer | Targets | Applications of diseases | Approved years or current phases of clinical trials |
---|---|---|---|---|---|
Crizotinib | Xalkori | Pfizer Inc | ALK, ROS1, MET | Locally advanced or metastatic ALK + NSCLC | 2011 [50] |
Metastatic ROS1 + NSCLC | 2016 [67] | ||||
Advanced METex14 + or MET-amplified NSCLC | |||||
Alectinib | Alecensa | Genentech Inc | ALK | Unresectable, advanced or recurrent ALK + NSCLC | 2014§ |
2L metastatic ALK + NSCLC, 1L metastatic ALK + NSCLC | |||||
Ceritinib | Zykardia | Novartis | ALK, ROS1 | 2L metastatic ALK + NSCLC | 2014 |
1L metastatic ALK + NSCLC | 2017 [198] | ||||
Advanced ROS1 + NSCLC | II [199] | ||||
Brigatinib | Alunbrig | Takeda | ALK | 2L metastatic ALK + NSCLC | 2017 |
1L metastatic ALK + NSCLC | |||||
Combined with cetuximab for EGFR/T790M/cis-C797S NSCLC | [43] | ||||
Ensartinib | - | Beta/Xcovery Holdings Inc | ALK | 2L metastatic ALK + NSCLC | 2019 a priority review by NMPA [52] |
Entrectinib | Rozlytrek | Genentech Inc | ROS1, TRK, ALK | Metastatic ROS1 + NSCLC | 2019 [68] |
TRK fusion + solid tumors | 2019 [200] | ||||
Lorlatinib | Lorbrena | Pfizer Inc | ALK, ROS1 | 2-3L metastatic ALK + NSCLC | 2018§ [64] |
Investigational drugs | |||||
Repotrectinib | - | Turning Point | ROS1, TRK, ALK | Advanced ROS1 + NSCLC | I [70] |
DS-6051b | - | Daiichi Sankyo | ROS1, TRK | ROS1 + NSCLC | I [72] |
TRK + /ROS1 + solid tumors | I [201] | ||||
WX-0593 | - | Qilun | ALK, ROS1 | ALK + or ROS1+ NSCLC | I [61] |
CT-707 | - | Centaurus | ALK, FAK, Pyk2 | 2L advanced ALK + NSCLC | I [62] |
CT-3505 | - | Shouyao Holdings | ALK | ALK + NSCLC | I (ChiCTR1900025619) |